Helen J. Gogas, MD, PhD
Updated results from the phase III COLUMBUS trial show continued prolonged progression-free and overall survival (OS) with the combination of encorafenib (Braftovi) and binimetinib (Mektovi) compared with BRAF inhibition alone in patients with advanced/metastatic BRAF
In part 1 of the international COLUMBUS study, 577 patients with BRAF
V600E/K mutation-positive unresectable or metastatic melanoma were randomized 1:1:1 to receive encorafenib 450 mg twice daily in combination with binimetinib 45 mg twice daily (n = 192), encorafenib alone at 300 mg daily (n = 194), or vemurafenib 960 mg twice daily (n = 191).
... to read the full story